KRAS and neoplasm: In this study, we characterized the heterogeneity of genetic variations accompanying low-frequency KRAS mutations detected in plasma ctDNA of six pretreated mCRC patients and analyzed the clinical course of these patients to evaluate the potential prognostic value of low-frequency ctDNA KRAS mutations in the differential determination of tumor progression and treatment response.